Host Pathogen Variation & TB Pathogenesis

宿主病原体变异

• 批准号: 10271168
• 负责人: JEFFERY S COX
• 金额: $ 263.89万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10271168
• 关键词: Area; Bacillus; Bioinformatics; Biological; Cells; Clinical; Clinical Management; Clinical Treatment; Data; Data Management Resources; Data Set; Disease; Exposure to; Genes; Genetic; Genetic Variation; Genomics; Heterogeneity; Human; Human Genetics; Immune; Immune system; Infection; Integration Host Factors; Lung diseases; Medical Genetics; Meningeal Tuberculosis; Meningitis; Methods; Modeling; Molecular; Mus; Mycobacterium tuberculosis; Outcome; Pathogenesis; Pathway interactions; Pharmaceutical Preparations; Pharmacotherapy; Predisposition; Prevention strategy; Process; Proteins; Proteomics; Pulmonary Tuberculosis; Resistance; Resistance to infection; Source; Testing; Treatment Protocols; Tuberculosis; Uganda; Vaccines; Variant; Vietnam; Work; biomarker discovery; clinical phenotype; cohort; experimental study; follow-up; gene product; genetic information; genetic variant; genome-wide; human pathogen; immunomodulatory therapies; in vivo; innovation; insight; latent infection; macrophage; mouse model; multidisciplinary; multiple omics; novel; novel marker; pathogen; pressure; prevent; programs; protein function; resistance mechanism; response; synergism; transcriptome sequencing; transmission process; treatment duration; treatment strategy

Hurdles for controlling tuberculosis (TB) include developing a highly efficacious vaccine, preventing transmission and infection in endemic areas, and discovering drug treatment regimens that work rapidly and kill dormant bacilli within macrophages. After exposure to Mycobacterium tuberculosis (Mtb), outcomes vary widely including resistance, asymptomatic latent infection, active pulmonary disease, and disseminated infections including TB meningitis (TBM). This heterogeneity complicates clinical treatment decisions with regards to choosing the number of drugs and duration of treatment. This broad clinical spectrum also presents a unique opportunity for understanding the biological mechanisms that control TB pathogenesis. A major source of heterogeneity is a combination of genetic variation in both humans and Mtb that are evolving under constant selective pressure. Our overall program objective is to use genetic, genomic, proteomic, and bioinformatic strategies to discover host and pathogen variants of genes and gene products that are associated with TB clinical outcomes and to determine how these variants interact to regulate molecular, cellular, and in vivo functions. Our strategy is anchored upon two powerful cohorts in Vietnam and Uganda (Core A) that capture the full spectrum of resistance to traditional LTBI (latent TB infection), LTBI, pulmonary TB disease, and disseminated disease in the form of TBM. Core A examines paired host and Mtb genetic data and the association with these diverse clinical outcomes. In Project 1, we use genetic and new proteomic strategies to examine how the Mtb genes and variants identified by Core A function and how the encoded proteins interact with and regulate macrophage responses. In Project 2, we use human genetic methods along with proteomic strategies in macrophages to uncover regulatory host genes and variants that are associated with resistance to Mtb infection and/or disseminated TB. In Project 3, we examine in vivo mechanisms of transmission and dissemination that are attributed to specific host genes and pathways and Mtb variants, employing a new and powerful mouse model of infection that recapitulates many of the manifestations that occur in human TB. Core B uses pathway-driven and novel bioinformatics approaches to integrate the genetic results from Core A with the multiple large-scale and diverse datasets to dynamically identify and prioritize pathways and protein networks for functional testing. Together, this multidisciplinary program and strategy will enable us to test our overall hypothesis that variants of Mtb and host genes dictate heterogeneous clinical outcomes and encode factors that interact with and alter innate immune cells. We will use genetic, genomic, proteomic, and bioinformatic strategies to examine variation in Mtb and its paired human host to examine mechanisms of resistance and susceptibility to infection and disease with discovery of biomarkers for clinical management and novel immunomodulatory therapies.

控制结核病的障碍包括开发一种高效的疫苗、预防